Cargando…
Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells
Human endothelial cells are initiators and targets of the rejection response. Pre-operative modification of endothelial cells by small interfering RNA transfection could shape the nature of the host response post-transplantation. Ablation of endothelial cell class II major histocompatibility complex...
Autores principales: | Cui, Jiajia, Qin, Lingfeng, Zhang, Junwei, Abrahimi, Parwiz, Li, Hong, Li, Guangxin, Tietjen, Gregory T., Tellides, George, Pober, Jordan S., Mark Saltzman, W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543113/ https://www.ncbi.nlm.nih.gov/pubmed/28775323 http://dx.doi.org/10.1038/s41467-017-00297-x |
Ejemplares similares
-
Ex vivo isolated human vessel perfusion system for the design and assessment of nanomedicines targeted to the endothelium
por: Lysyy, Taras, et al.
Publicado: (2020) -
Knockdown of TNFR1 by the sense strand of an ICAM-1 siRNA: dissection of an off-target effect
por: Clark, Paul R., et al.
Publicado: (2008) -
Therapeutic siRNA silencing in inflammatory monocytes
por: Leuschner, Florian, et al.
Publicado: (2011) -
Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2
por: Wang, Chen, et al.
Publicado: (2014) -
Therapeutic siRNA: Principles, Challenges, and Strategies
por: Gavrilov, Kseniya, et al.
Publicado: (2012)